Antibodies as key mediators of protection against Mycobacterium tuberculosis DOI Creative Commons
Qixin Wang, Deepika Nag, Susan L. Baldwin

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 2, 2024

Tuberculosis (TB) is caused by infection with the bacterial pathogen Mycobacterium tuberculosis (M.tb) in respiratory tract. There was an estimated 10.6 million people newly diagnosed TB, and there were approximately 1.3 deaths TB 2022. Although global prevalence of has remained high for decades annual leading cause death attributed to infectious diseases, only one vaccine, Bacillus Calmette–Guérin (BCG), been approved so far prevent/attenuate disease. Correlates protection or immunological mechanisms that are needed control M.tb remain unknown. The protective role antibodies after BCG vaccination also largely unclear; however, recent studies have provided evidence their involvement against disease, as biomarkers state infection, potential predictors outcomes. Interestingly, generated post-vaccination linked activation innate immune cascades, providing further antibody effector functions critical pathogens such M.tb. In this review, we aim provide current knowledge application diagnosis, prevention, treatment. Particularly, review will focus on 1) preventing infections through Mtb adherence epithelium, antibody-mediated phagocytosis, cellular cytotoxicity; 2) M.tb-directed response how humoral profiles different glycosylation patterns these disease state; 3) How immunity can be explored early diagnosis detection methods combat burden. Broadening paradigm differentiated profiling antibody-based during progression offers new directions treatment, preventative strategies. This approach involves linking aforementioned responses state, progression, clearance.

Language: Английский

Antibodies as key mediators of protection against Mycobacterium tuberculosis DOI Creative Commons
Qixin Wang, Deepika Nag, Susan L. Baldwin

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 2, 2024

Tuberculosis (TB) is caused by infection with the bacterial pathogen Mycobacterium tuberculosis (M.tb) in respiratory tract. There was an estimated 10.6 million people newly diagnosed TB, and there were approximately 1.3 deaths TB 2022. Although global prevalence of has remained high for decades annual leading cause death attributed to infectious diseases, only one vaccine, Bacillus Calmette–Guérin (BCG), been approved so far prevent/attenuate disease. Correlates protection or immunological mechanisms that are needed control M.tb remain unknown. The protective role antibodies after BCG vaccination also largely unclear; however, recent studies have provided evidence their involvement against disease, as biomarkers state infection, potential predictors outcomes. Interestingly, generated post-vaccination linked activation innate immune cascades, providing further antibody effector functions critical pathogens such M.tb. In this review, we aim provide current knowledge application diagnosis, prevention, treatment. Particularly, review will focus on 1) preventing infections through Mtb adherence epithelium, antibody-mediated phagocytosis, cellular cytotoxicity; 2) M.tb-directed response how humoral profiles different glycosylation patterns these disease state; 3) How immunity can be explored early diagnosis detection methods combat burden. Broadening paradigm differentiated profiling antibody-based during progression offers new directions treatment, preventative strategies. This approach involves linking aforementioned responses state, progression, clearance.

Language: Английский

Citations

2